Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical suspension formulation comprising
   a. particles of formoterol or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
   b. particles of ciclesonide or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation and
   c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof.

2. (Currently amended) The pharmaceutical suspension formulation according to claim 1 comprising
   a. particles of micronized formoterol, or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
   b. particles of micronized ciclesonide or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,
   c. ethanol,

d. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and

e. optionally <u>further comprising</u> a surfactant.

3. (Previously presented) The pharmaceutical suspension formulation according to claim 1 containing less than 3% by weight of ethanol.

4. (Currently amended) The pharmaceutical suspension formulation according to claim 1 comprising

a. particles of micronized formoterol, or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,

b. particles of micronized ciclesonide or a pharmaceutically acceptable salt~~, solvate or physiologically functional derivative~~ thereof, said particles being suspended in the formulation,

c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof and

d. a surfactant.

5. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises R,R-formoterol.

6. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises formoterol fumarate dihydrate.

7. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises oleic acid as surfactant.

8. (Currently amended) The pharmaceutical suspension formulation according to claim [[1]] 7 which comprises about 0.001 to 0.1 % (w/w) of oleic acid.

9. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises HFA 227 as propellant.

10. (Currently amended) The pharmaceutical suspension formulation according to claim 1 further comprising disodium chromoglycate at a concentration which is not therapeutically and/or prophylactically active.

11. (Previously presented) The pharmaceutical suspension formulation according to claim 1, which is administered in a once daily dosing regimen.